According to immunohistochemical analysis of tumor tissues obtained before combination therapy, we found the patients with high expression of LAYN (LAYNhi) in the good-responders group accounted for 75%, low expression of LAYN (LAYNlo) in the good-responders group accounted for 25%, in contrast, 25% patients with high expression of LAYN (LAYNhi) and 75% patients with low expression of LAYN (LAYNlo) were observed in the poor-responders group (Fig. 6f, g). The gene discussed is LAYN; the disease is neoplasm.